Cyclo Therapeutics, INC
Market Movers (8-K)
Rafael Holdings finalizes its merger with Cyclo Therapeutics, issuing shares and warrants, and focusing on the TransportNPC trial for Niemann-Pick Disease Type C1.
Cyclo Therapeutics stockholders voted to approve the merger agreement with Rafael Holdings at a special meeting held on March 20, 2025.
Cyclo Therapeutics entered into a Ninth Amended and Restated Note Purchase Agreement with Rafael Holdings, issuing a $2.5 million convertible promissory note.
Capital raise
Cyclo Therapeutics extends its merger agreement deadline with Rafael Holdings to March 31, 2025, and secures an additional $2 million in convertible promissory notes from Rafael.
Delay expected
Capital raise
Cyclo Therapeutics received a notice from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, potentially leading to delisting.
Worse than expected
Delay expected
Cyclo Therapeutics has entered into a seventh amended agreement with Rafael Holdings, securing a $3 million convertible promissory note to be used for working capital and general corporate purposes.
Worse than expected
Capital raise
Quarterly Earnings (10-Q)
10-Q: Cyclo Therapeutics Reports Q3 2024 Results Amidst Proposed Merger and Nasdaq Compliance Challenges
Cyclo Therapeutics reported a net loss for Q3 2024, a decrease in revenue, and is navigating a proposed merger with Rafael Holdings while addressing Nasdaq listing compliance issues.
Worse than expected
Capital raise
Cyclo Therapeutics announced its Q2 2024 financial results, highlighted by the completion of enrollment in its pivotal Phase III clinical trial for Niemann-Pick Type C disease (NPC) and a net loss of $10.3 million for the first six months of 2024.
Worse than expected
Capital raise
Cyclo Therapeutics saw a 33% increase in revenue and a reduced net loss in the first quarter of 2024 compared to the same period last year, while also highlighting ongoing clinical trials and financial challenges.
Worse than expected
Capital raise
Annual Reports (10-K)
Cyclo Therapeutics files an amendment to its annual report, detailing a recent merger, clinical trial updates, and financial results for the year ended December 31, 2023.
Worse than expected
Capital raise
Cyclo Therapeutics has filed an amendment to its 2023 annual report to address SEC comments and provide additional details regarding its merger with Applied Molecular Transport, Inc.
Worse than expected
Capital raise
Cyclo Therapeutics has filed an amendment to its annual report to include previously omitted information regarding principal accountant fees and services.
Cyclo Therapeutics, Inc.'s annual 10-K filing provides a detailed overview of the company's securities, including common stock and warrants, as well as anti-takeover provisions and recent business activities.
Worse than expected
Capital raise
Insider Trading (Form 4)
Form 4: Cyclo Therapeutics Director William Conkling Receives Stock Grant in Lieu of Cash Compensation
Director William Conkling of Cyclo Therapeutics, Inc. received 27,654 shares of common stock as compensation in lieu of cash.
Director Vivien Wong of Cyclo Therapeutics, Inc. received 25,140 shares of common stock as compensation in lieu of cash.
Form 4: Cyclo Therapeutics Director Shawn Cross Reports Acquisition of Shares in Lieu of Cash Compensation
Director Shawn Cross acquired 28,597 shares of Cyclo Therapeutics common stock on February 27, 2025, in lieu of cash compensation.
Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired 33,311 shares of common stock as compensation in lieu of cash.
Director C.E. Rick Strattan acquired 30,169 shares of Cyclo Therapeutics common stock in lieu of cash compensation.
Director Francis Patrick Ostronic acquired 70,329 shares of Cyclo Therapeutics common stock in lieu of cash compensation.